CMPX实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases...

Stats
今日成交量	65 665.00
平均成交量	375 306
市值	184.85M
EPS	$0 ( 2024-03-20 )
下一个收益日期	( $0 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.39
ATR14	$0.0120 (0.83%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-08	Boylan James P	Buy	40 000	Stock Option (Right to Buy)
2024-02-09	Gray Mary Ann	Buy	40 000	Stock Option (Right to Buy)
2024-02-09	Lindahl Richard S	Buy	40 000	Stock Option (Right to Buy)
2024-02-09	Gordon Carl L	Buy	40 000	Stock Option (Right to Buy)
2024-02-09	Chiniara Ellen	Buy	40 000	Stock Option (Right to Buy)

INSIDER POWER
93.94
Last 94 transactions
Buy: 28 287 388 \| Sell: 226 920

音量相关性

長: 0.04 (neutral)

短: 0.05 (neutral)

Signal:(49.093) Neutral

Compass Therapeutics, 相关性

10 最正相关
PIXY	0.935
WTBA	0.915
UPC	0.91
LLNW	0.909
GSMG	0.908
ALXO	0.905
ENNV	0.902
YJ	0.902
BMRA	0.897
LVTX	0.893

10 最负相关
HHGC	-0.937
KYCH	-0.936
UONE	-0.936
OLED	-0.931
PPD	-0.93
SIBN	-0.927
CDNS	-0.927
NVTS	-0.923
ALYA	-0.923
MELI	-0.923

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Compass Therapeutics, 相关性 - 货币/商品

-0.60
( weak negative )

-0.36
( neutral )

0.00
( neutral )

-0.46
( neutral )

0.00
( neutral )

0.41
( neutral )

Compass Therapeutics, 财务报表

Annual	2022
营收:	$0
毛利润:	$-1.90M (0.00 %)
EPS:	$-0.350

FY	2022
营收:	$0
毛利润:	$-1.90M (0.00 %)
EPS:	$-0.350

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.583

FY	2020
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-0.566

Financial Reports:

No articles found.

Compass Therapeutics,

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

实时更新： Compass Therapeutics, [CMPX]

Upcoming Earnings Alert